[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100631590":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":15,"locations":21,"responsibleParty":38,"collaborators":10,"id":40,"slug":41,"hasResults":42,"nctId":43,"briefTitle":44,"officialTitle":44,"acronym":45,"eligibilityCriteria":46,"healthyVolunteers":42,"sex":47,"minAge":48,"maxAge":10,"enrollmentInfo":49,"targetDuration":10,"studyType":52,"phases":10,"briefSummary":53,"conditions":54,"keywords":10,"overallStatus":24,"whyStopped":10,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":69},{"fullName":5,"class":6},"Ray Therapeutics, Inc.","INDUSTRY",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"Retinitis Pigmentosa",null,"Up to 25 patients with Retinitis Pigmentosa",{"label":13,"type":10,"description":14,"interventionNames":10},"Other Retinal Dystrophies","Up to 25 patients with Other Retinal Dystrophies",[16],{"name":17,"role":18,"phone":19,"phoneExt":10,"email":20},"Reem Jaber, MS, CGC","CONTACT","949-264-3793","info@vr-ai.com",[22],{"facility":23,"status":24,"city":25,"state":26,"zip":27,"country":28,"countryCode":29,"cosmosGeoPoint":30,"geoPoint":35,"contacts":36},"Vision Research and Assessment Institute","RECRUITING","Irvine","California","92614","United States","US",{"type":31,"coordinates":32},"Point",[33,34],-117.82311,33.66946,{"lat":34,"lon":33},[37],{"name":17,"role":18,"phone":19,"phoneExt":10,"email":20},{"type":39,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100631590","development-and-evaluation-of-functional-visual-field-and-navigation-endpoints-in-moderate-to-profound-inherited-retinal-disease-define-ird-100631590",false,"NCT07502664","Development and Evaluation of Functional Visual Field and Navigation Endpoints in Moderate to Profound Inherited Retinal Disease (DEFINE-IRD)","DEFINE-IRD","Inclusion Criteria:\n\n* Diagnosis of bilateral retinitis pigmentosa (RP) or other retinal dystrophies impacting peripheral vision as confirmed from previous eye examination records\n* Best-corrected visual acuity between 20\u002F200 to HM in at least one eye.\n* Reasonably fluent in English or Spanish\n\nExclusion Criteria:\n\n* Cognitive impairment, memory loss or dementia sufficient in severity to preclude informed consent or in the opinion of the investigator would prevent satisfactory completion of some or all of the testing.\n* Any circumstance that in the opinion of the investigator, would interfere with participation in, or compliance with the study protocol\n* Current pregnancy as reported by patient","ALL","18 Years",{"count":50,"type":51},25,"ESTIMATED","OBSERVATIONAL","The Vision Research and Assessment Institute (VRAI) was established with the purpose of serving as a testing facility for efficacy endpoints for patients with Low Vision.\n\nThe mission of the VRAI is to enable the highest quality, standardized efficacy testing of patients with visual impairment.\n\nThe VRAI facilitates the development and refinement of existing endpoints specifically for testing patients with Low Vision.",[9,55,56,57,58,59],"Stargardt Macular Dystrophy","Stargardt Disease","Geographic Atrophy From Age-related Macular Degeneration","X-linked Retinoschisis","Retinal Dystrophies","2026-03-24",{"date":62,"type":63},"2026-03-31","ACTUAL",{"date":65,"type":63},"2026-02-19",{"date":67,"type":51},"2027-02",{"name":5,"class":6},1]